Progressive lung disease refers to a group of chronic respiratory disorders characterized by a gradual decline in lung structure and function over time. Conditions such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and certain interstitial lung diseases are commonly included in this category, each presenting with distinct pathological mechanisms but sharing the outcome of persistent respiratory impairment. The hallmark of progressive lung disease is irreversible scarring, inflammation, or remodeling of lung tissue, leading to worsening breathlessness, reduced exercise tolerance, and frequent exacerbations. Diagnosis often requires a comprehensive evaluation with pulmonary function tests, imaging studies like high-resolution CT scans, and in some cases, genetic or biomarker testing to identify underlying causes. While curative treatments remain limited, management strategies focus on slowing disease progression, alleviating symptoms, and preventing complications. Pharmacological approaches may include antifibrotic agents, bronchodilators, or anti-inflammatory therapies, alongside oxygen supplementation and pulmonary rehabilitation programs that enhance quality of life. Early referral for lung transplantation is also considered in advanced stages when conventional therapies fail. Patient education, lifestyle modification, and proactive monitoring are essential to optimize long-term outcomes. Current research into molecular mechanisms, precision medicine, and regenerative therapies offers hope for more effective interventions. By combining evidence-based management with emerging innovations, the approach to progressive lung disease aims not only to extend survival but also to preserve independence and improve daily living for those affected.
Title : Screening questionnaires for obstructive sleep apnea: An updated systematic review
Behzad Rahmati, Isfahan University of Medical Sciences, Iran (Islamic Republic of)
Title : Improving covid 19 candidate vaccine response through probiotics and micronutrient supplementation: Evaluating the role of TLR5
Zohre Eftekhari, Biotechnology Research Center, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Iatrogenic pneumothorax following nephrectomy: Case report
Chaimae Tahiri, National University Hospital Center of Fann, Senegal